



(51) International Patent Classification:

A61K 31/439 (2006.01) A61K 31/529 (2006.01)
A61K 31/4985 (2006.01) A61K 31/53 (2006.01)
A61K 31/504 (2006.01) A61K 31/5377 (2006.01)
A61K 31/506 (2006.01) A61K 39/395 (2006.01)
A61K 31/517 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/052874

(22) International Filing Date:

24 October 2024 (24.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/593,222	25 October 2023 (25.10.2023)	US
63/572,068	29 March 2024 (29.03.2024)	US
63/683,193	14 August 2024 (14.08.2024)	US

(71) Applicant: **KUMQUAT BIOSCIENCES INC.** [US/US];
10770 Wateridge Circle, Suite 120, San Diego, California
92121 (US).


(72) Inventors: **LIU, Yi**; 10770 Wateridge Circle, Suite 120,
San Diego, California 92121 (US). **JANES, Matthew R.**;
10770 Wateridge Circle, Suite 120, San Diego, 92121 (US).
HANSEN, Rasmus; 10770 Wateridge Circle, Suite 120,
San Diego, California 92121 (US).

(74) Agent: **MALECHA, James** et al.; Wilson Sonsini
Goodrich & Rosati, 650 Page Mill Road, Palo Alto, Cali-
fornia 94304 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: COMBINATIONS OF SOS-1 INHIBITORS WITH OSIMERTINIB AND/OR MET INHIBITORS TO TREAT CANCER

FIG. 7



(57) Abstract: The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, the subject compositions and methods are useful for reducing signaling output of oncogenic proteins when used in combination with one or more other therapeutic agents.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*